text
"['\nIX. 계열회사 등에 관한 사항\n가. 계열회사 출자\xa0현황기업집단의 명칭: 셀트리온(주)셀트리온은「독점규제 및 공정거래에 관한 법률」상 셀트리온그룹에 속한 계열회사로서 2020년 4분기말 현재 계열회사 현황은 아래와 같습니다.\xa0\n(기준일: 2020년 12월 31일)\n(단위 : %)\n계열회사명\n사업자등록번호\n투 \xa0자 \xa0자\n서 정 진\n㈜셀트리온\n㈜셀트리온홀딩스\n㈜셀트리온헬스케어\n㈜셀트리온헬스케어홀딩스\n㈜셀트리온스킨큐어\n㈜셀트리온제약\n계\n㈜셀트리온\n133-81-23603\n-\n-\n20.02\n-\n-\n2.12\n-\n22.14\n㈜셀트리온홀딩스\n131-86-24858\n95.51\n\xa0-\n-\n\xa0-\n-\n\xa0-\n\xa0-\n95.51\n㈜셀트리온헬스케어\n123-81-53473\n11.21\n\xa0-\n\xa0-\n\xa0-\n24.33\n1.39\n\xa0-\n36.92\n㈜셀트리온헬스케어홀딩스\n480-86-01873\n100.00\n100.00\n㈜셀트리온스킨큐어\n105-86-13560\n70.23\n\xa0-\n\xa0-\n\xa0-\n-\n\xa0-\n\xa0-\n70.23\n㈜셀트리온제약\n214-86-71641\n\xa0-\n54.96\n-\n\xa0-\n-\n\xa0-\n\xa0-\n54.96\n㈜셀트리온엔터테인먼트\n107-87-63802\n\xa0-\n\xa0-\n100.00\n\xa0-\n-\n\xa0-\n\xa0-\n100.00\n㈜셀트리온 충북대 바이오메딕스\n417-87-01299\n-\n50.00\n-\n-\n-\n-\n-\n50.00\n㈜셀트리온 충북대 코스메틱스\n338-88-01033\n-\n-\n-\n-\n-\n50.00\n-\n50.00\n나. 회사와 계열회사간 임원 겸직 현황\n성명\n계열회사 겸직현황\n회사명\n직위\n상근여부\n서정진\n셀트리온홀딩스\n사내이사\n상근\n셀트리온제약\n사내이사\n상근\n셀트리온헬스케어\n사내이사\n상근\n셀트리온헬스케어홀딩스\n사내이사\n상근\n셀트리온엔터테인먼트\n기타비상무이사\n비상근\n다. 타법인출자 현황\n(기준일 :\xa0\n2020년 12월 31일\n)\n(단위 : 천원, 주, %)\n법인명\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\nA&G Pharmaceutical, Inc (비상장)\n2006.07.14\n신약개발투자\n2,676,548\n987,889\n17\n107,289\n0\n0\n9,059\n987,889\n17\n116,349\n1,971,082\n-314,586\xa0\n셀트리온 유럽 (비상장)\n2009.07.21\n유럽임상관련투자\n2\n1\n100\n2\n0\n0\n0\n1\n100\n2\n2\n0\xa0\n바이오톡스텍 (상장)\n2009.07.28\n투자수익\n2,025,000\n1,631,134\n11\n10,243,521\n0\n0\n14,549,715\n1,631,134\n11\n24,793,236\n60,584,722\n-1,410,890\xa0\n보스톤 인큐베이션투자조합(비상장)\n2009.11.27\n투자수익\n2,500,000\n11\n25\n83,007\n0\n0\n0\n11\n25\n83,007\n336,194\n-2,342\xa0\n셀트리온 예브라지아 (비상장)\n2009.12.09\n사업다각화\n392\n1\n100\n393\n-1\n-393\n0\n0\n0\n0\n393\n0\xa0\n제이티비씨 (비상장)\n2017.09.20\n투자수익\n500,000\n100,000\n0\n44,896\n0\n0\n-10,956\n100,000\n0\n33,940\n293,083,720\n-24,879,636\xa0\n프리미어 글로벌이노베이션 1호(비상장)\n2017.06.15\n유망 바이오벤처기업투자\n250,000\n3,482\n7\n3,333,335\n-37\n-36,933\n148,365\n3,445\n7\n3,444,767\n101,703,912\n26,759,066\xa0\n프리미어 글로벌이노베이션 2호(비상장)\n2020.11.05\n유망 바이오벤처기업투자\n250,000\n0\n0\n0\n250\n250,000\n0\n250\n6\n250,000\n4,500,138\n-188,067\xa0\n매일방송 (비상장)\n2011.03.17\n투자수익\n1,000,000\n250,981\n0\n1,475,167\n0\n0\n0\n250,981\n0\n1,475,167\n392,574,137\n5,632,910\xa0\n뉴스1 (비상장)\n2011.06.09\n투자수익\n500,000\n60,000\n5\n202,251\n0\n0\n97,749\n60,000\n5\n300,000\n18,409,363\n2,005,109\xa0\n셀트리온제약 (상장)\n2013.04.23\n경영참가 등\n50,057,259\n18,744,943\n55\n255,342,176\n937,247\n0\n0\n19,682,190\n55\n255,342,176\n548,074,598\n20,936,032\xa0\n2014 성장사다리-IMM벤처펀드(비상장)\n2014.08.11\n투자수익\n2,000,000\n3,793\n20\n2,977,244\n-1,293\n-1,293,400\n0\n2,500\n20\n1,683,844\n9,083,445\n-1,724,638\xa0\n미래에셋셀트리온신성장투자조합 1호 (비상장)\n2017.03.31\n유망 바이오벤처기업투자\n6,250,000\n438\n50\n43,750,000\n-13\n-1,250,000\n0\n425\n50\n42,500,000\n92,202,238\n5,895,763\xa0\nCelltrion Global Safety Data Center(비상장)\n2018.05.23\n글로벌 의약품안전성 데이터 관리\n1,106,930\n580,564\n100\n1,204,581\n0\n0\n0\n580,564\n100\n1,204,581\n1,896,634\n200,712\xa0\nCelltrion USA, Inc.(비상장)\n2018.07.24\n케미컬의약품판매유통망 구축\n38,973\n1,000\n100\n2,332,531\n2,050\n4,619,070\n0\n3,050\n100\n6,951,601\n12,816,032\n-8,632,880\xa0\nCelltrion Group Hongkong ltd (비상장)\n2019.04.01\n바이오의약품중국사업\n5,680,500\n7,000,000\n70\n8,059,100\n23,270\n27,265\n0\n7,023,270\n70\n8,086,365\n29,554,539\xa0\n-547,241\xa0\n셀트리온충북대바이오메딕스 (비상장)\n2018.07.18\n신약 및 원료의약품연구개발\n100,000\n20,000\n50\n100,000\n0\n0\n0\n20,000\n50\n100,000\n152,990\xa0\n-15,974\xa0\nCelltrion Asia Pacific PTE (비상장)\n2020.11.23\n케미컬의약품 판매및 연구개발\n315,987,120\n0\n0\n0\n283,600,000\n315,987,120\n0\n283,600,000\n100\n315,987,120\n325,408,677\xa0\n-3,294,286\xa0\n합 계\n29,384,237\n-\n329,255,493\n284,561,473\n318,302,729\n14,793,932\n313,945,710\n-\n662,352,155\n1,892,352,816\n20,419,052\n']"
